Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Post by carduon Nov 20, 2009 3:41pm
629 Views
Post# 16509266

From the other board.

From the other board.Is this history repeating itself?


Five years ago Thompson and co. entered into a bought deal with Canaccord.

>>11/5/2004 8:19:12 AM ET News Release Index

Oncolytics Biotech Inc. Enters into a Bought Deal Financing for $10 Million

CALGARY, AB, ---November 5, 2004 - Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) announced today that is has entered into a bought deal agreement with Canaccord Capital Corporation. Under the agreement, Canaccord has agreed to purchase 1,504,000 units (the "Units") at a price of $6.65 per Unit, resulting in gross proceeds to Oncolytics of $10,001,600. Each Unit consists of one common share and one-half of one common share purchase warrant, with each whole common share purchase warrant entitling the holder to acquire one common share upon payment of $8.00 per share for a period of 36 months following the closing date. The net proceeds from the offering will be used to expand and accelerate Oncolytics’ clinical trial programs and for general corporate purposes. The offering is expected to close on or about November 25, 2004.<<

In exchange for 10 million dollars Thompson and Co. gave a notoriously shady hedge fund (Amaranth) 1.5 million shares (of which Amaranth promptly disposed) and the accompanying warrants which Amaranth then used as a hedge as they shorted Oncolytics stock for well over a year, running the share price down from over C $7 to under $4 -- roughly a 50% drop.

Thompson's deal with the devil sent Oncolytics stock into a tailspin from which it has taken years to begin to recover and has left thousands of individual investors so far underwater that it's taken nearly five years for them to begin seriously comtemplating returning to even in their investments.

And then, just as things are looking up for those thousands of investors, Thompson and the gang do this.

Seems Thompson enjoys making history rhyme. If only, for the sake of longterm investors, he were a better poet.
Bullboard Posts